

**The American Journal of Human Genetics, Volume 108**

**Supplemental information**

**Fast two-stage phasing of  
large-scale sequence data**

**Brian L. Browning, Xiaowen Tian, Ying Zhou, and Sharon R. Browning**

## Supplemental Data

### Additional Acknowledgments

We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. Funding for the Barbados Asthma Genetics Study was provided by National Institutes of Health (NIH) R01HL104608, R01HL087699, and HL104608 S1. The Mount Sinai BioMe Biobank has been supported by The Andrea and Charles Bronfman Philanthropies and in part by funds from the NHLBI and the National Human Genome Research Institute (NHGRI) (U01HG00638001; U01HG007417; X01HL134588); genome sequencing was funded by contract HHSN268201600037I. The Cleveland Clinic Atrial Fibrillation study was supported by NIH grants R01 HL 090620 and R01 HL 111314, the NIH National Center for Research Resources for Case Western Reserve University and Cleveland Clinic Clinical and Translational Science Award UL1-RR024989, the Cleveland Clinic Department of Cardiovascular Medicine philanthropy research funds, and the Tomsich Atrial Fibrillation Research Fund; genome sequencing was supported by R01HL092577. The Framingham Heart Study was supported by contracts NO1-HC-25195, HHSN268201500001I and 75N92019D00031 from the NHLBI and grant supplement R01 HL092577-06S1; genome sequencing was funded by HHSN268201600034I and U54HG003067. The Hypertension Genetic Epidemiology Network Study is part of the NHLBI Family Blood Pressure Program; collection of the data represented here was supported by grants U01 HL054472, U01 HL054473, U01 HL054495, and U01 HL054509; genome sequencing was funded by R01HL055673. The Jackson Heart Study is supported and conducted in collaboration with Jackson State University (HHSN268201300049C and HHSN268201300050C), Tougaloo College (HHSN268201300048C), and the University of Mississippi Medical Center (HHSN268201300046C and HHSN268201300047C) contracts from NHLBI and the National Institute for Minority Health and Health Disparities (NIMHD); genome sequencing was funded by HHSN268201100037C. The My Life, Our Future samples and data are made possible through the partnership of Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National

Hemophilia Foundation, and Bioverativ; genome sequencing was funded by HHSN268201600033I and HHSN268201500016C. The Severe Asthma Research Program was conducted with the support of the NHLBI grants R01 HL069116, R01 HL069130, R01 HL069149, R01 HL069155, R01 HL069167, R01 HL069170, R01 HL069174, R01 HL069349, U10 HL109086, U10 HL109146, U10 HL109152, U10 HL109164, U10 HL109168, U10 HL109172, U10 HL109250, and U10 HL109257; genome sequencing was funded by HHSN268201500016C. The Venous Thromboembolism project was funded in part by grants from the NIH, NHLBI (HL66216 and HL83141) and the NHGRI (HG04735). The Vanderbilt Genetic Basis of Atrial Fibrillation study was supported by grants from the American Heart Association (EIA 0940116N), and grants from the National Institutes of Health (HL092217, U19 HL65962, and UL1 RR024975), and by CTSA award (UL1TR000445) from the National Center for Advancing Translational Sciences; genome sequencing was funded by R01HL092577. The Women's Health Initiative program is funded by NHLBI through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005; genome sequencing was funded by HHSN268201500014C.